Umoja Biopharma
Umoja Biopharma is seeking a Senior Manager of Manufacturing to lead the Drug Substance Fill and Drug Product Manufacturing team at its Louisville, Colorado facility. This newly created role focuses on commercial launch readiness, process improvements, and ensuring high operational success rates for cell/gene therapy manufacturing. The position requires strong leadership, extensive cGMP manufacturing experience, and the ability to manage a team through growth and change.
Headquarters
Seattle, Washington, United States
Company Size
51-200 employees
Founded
2019
Umoja Biopharma is a biotechnology company advancing in vivo CAR T cell therapies for cancer using its VivoVec platform to generate CAR T cells directly inside a patient’s body. This approach aims to provide immediate drug availability, bypassing the weeks-to-months manufacturing timeline of traditional ex vivo CAR T therapies, and the company maintains in-house manufacturing to scale production and support its clinical pipeline.
Nona Biosciences Announces Expansion of Collaboration with Umoja Biopharma to Advance In Vivo CAR-T Cell Therapies
Nov 5, 2025
Umoja Biopharma Named One of 2025’s Most Promising Biotech Companies by Endpoints News and Fierce Biotech
Sep 23, 2025
Umoja secures $100M series C to bring more CAR-Ts into the clinic
Jan 14, 2025
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Umoja Biopharma.
Seattle immunotherapy startup Umoja Biopharma raises $100M
Jan 14, 2025